Loading...
•
Mar 31, 2022
Sorrento Q1 2022 Earnings Report
Reported continuous sales growth in ZTlido.
Key Takeaways
Scilex Holding Company reported preliminary gross sales of approximately $18.4 million for ZTlido in 1Q2022, representing a 26% growth compared to 1Q2021.
Preliminary gross sales for ZTlido in 1Q2022 were approximately $18.4 million.
ZTlido sales in 1Q2022 grew by 26% compared to 1Q2021.
March 2022 ZTlido sales were $8.1 million, a 53% increase year-over-year.
Scilex is focused on expanding payor coverage for ZTlido as a first-line therapy for neuropathic pain.
Sorrento
Sorrento
Sorrento Revenue by Segment
Revenue by Segment
ZTlido Revenue
CapyFin.com Forward Guidance
Scilex Holding Company and Vickers Vantage Corp. I entered into a definitive business combination agreement on March 17, 2022, with the closing expected by the third quarter of 2022.